quantic69
Eli Lilly (NYSE:LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 diabetes, by up to 170% in the UK starting in September.
The move comes as President Donald Trump has put pressure on pharma companies to align US drug prices to what they are in other parts of the world.
Lilly told the Financial Times the decision is to “address pricing inconsistencies compared with other developed countries, including in Europe.”
The monthly cost for the highest dosage strengths of the drug will increase from £122 to £330, a 170% surge. For lower doses, the price tag will jump from 45%-138%.
Lilly, however, said it was not raising the price for Mounjaro paid by the National Health Service to maintain enough supply.
“At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability,” Lilly told the FT. “With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation.”